Selective interstitial doxorubicin for recurrent glioblastoma

Related Experiment Video

Updated: Dec 31, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Valerii Matcovschii¹, Dan Lisii¹, Valentin Gudumac²

¹Neurosurgery Department Institute of Neurology Institute of Neurology and Neurosurgery Chisinau Moldova.

Clinical Case Reports

|January 2, 2020

Abstract:

Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood-brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far-infiltrated tumor cells.

Keywords:

doxorubicin glioblastoma interstitial chemotherapy recurrence stem cell culture

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...